ロード中...
Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis
Immunoproteasome (IP) inhibition holds potential as a novel treatment option for various immune-mediated pathologies. The IP inhibitor ONX 0914 reduced T cell cytokine secretion and Th17 polarization and showed pre-clinical efficacy in a range of autoimmune disorders, transplant-allograft rejection,...
保存先:
| 出版年: | Front Immunol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6212513/ https://ncbi.nlm.nih.gov/pubmed/30416500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02386 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|